4.8 Article

Bone mineral: A trojan horse for bone cancers. Efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin

Journal

MATERIALS TODAY BIO
Volume 14, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.mtbio.2022.100227

Keywords

Drug delivery; Nano and micro hydroxyapatite; Doxorubicin; Solid tumor; Osteosarcoma

Funding

  1. National Microscopy Infrastructure, NMI [VR-RFI 2019-00217]
  2. Swedish Research Council (Vetenskapsradet) [2021-03447]
  3. Berta Kamprad foundation [FBKS-2020-23-(269)]
  4. Maggie Stephens foundation [20202004]
  5. China Scholarship Council [201806940015]
  6. Cancerfonden [20 0711 PjF]
  7. Swedish Research Council [2021-03447] Funding Source: Swedish Research Council

Ask authors/readers for more resources

This study demonstrates that doxorubicin (DOX) modified hydroxyapatite (HA) nanoparticles can release DOX in osteosarcoma cells, inhibiting cell migration and inducing cell apoptosis. In a mouse osteosarcoma model, locally delivered DOX via HA particles has a stronger tumor eradication effect. Additionally, it is shown that HA nanoparticles play a pivotal role in this approach, and the combination of nano and micro HA can increase the safety of particulate nanomaterials.
Efficient systemic pharmacological treatment of solid tumors is hampered by inadequate tumor concentration of cytostatics necessitating development of smart local drug delivery systems. To overcome this, we demonstrate that doxorubicin (DOX), a cornerstone drug used for osteosarcoma treatment, shows reversible accretion to hydroxyapatite (HA) of both nano (nHA) and micro (mHA) size. nHA particles functionalized with DOX get engulfed in the lysosome of osteosarcoma cells where the acidic microenvironment causes a disruption of the binding between DOX and HA. The released DOX then accumulates in the mitochondria causing cell starvation, reduced migration and apoptosis. The HA+DOX delivery system was also tested in-vivo on osteosarcoma bearing mice. Locally delivered DOX via the HA particles had a stronger tumor eradication effect compared to the controls as seen by PET-CT and immunohistochemical staining of proliferation and apoptosis markers. These results indicate that in addition to systemic chemotherapy, an adjuvant nHA could be used as a carrier for intracellular delivery of DOX for prevention of tumor recurrence after surgical resection in an osteosarcoma. Furthermore, we demonstrate that nHA particles are pivotal in this approach but a combination of nHA with mHA could increase the safety associated with particulate nanomaterials while maintaining similar therapeutic potential.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available